He is especially focused on the evaluation of novel, targeted therapies and immunotherapies. As a 2016 Lymphoma Research Foundation Scholar for the Lymphoma Clinical Research Mentoring Program, he investigated the efficacy of integrating a new BTK (Bruton’s tyrosine kinase) inhibitor (ACP-196) with standard mantle cell lymphoma (MCL) treatment, which frequently includes chemotherapy followed by an autologous stem cell transplant, to determine whether this combination leads to improved patient outcomes.